{"id":687720,"date":"2022-09-21T16:04:07","date_gmt":"2022-09-21T20:04:07","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-to-participate-in-the-cantor-oncology-hematology-hemeonc-conference\/"},"modified":"2022-09-21T16:04:07","modified_gmt":"2022-09-21T20:04:07","slug":"alx-oncology-to-participate-in-the-cantor-oncology-hematology-hemeonc-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-to-participate-in-the-cantor-oncology-hematology-hemeonc-conference\/","title":{"rendered":"ALX Oncology to Participate in the Cantor Oncology, Hematology &amp; HemeOnc Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p>SOUTH SAN FRANCISCO, Calif., Sept.  21, 2022  (GLOBE NEWSWIRE) &#8212; ALX Oncology Holdings Inc., (\u201cALX Oncology\u201d) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced that Jaume Pons, Ph.D., Founder, President and Chief Executive Officer, will participate in a panel and investor meetings at the Cantor Oncology, Hematology &amp; HemeOnc Conference on Wednesday, September 28 in New York.<\/p>\n<p align=\"justify\">Format: Moderated panel with analysts, Li Watsek &amp; Brandon Folkes<br \/>Panel: <em>\u201cBuilding Combinations: What are the Novel Ideas?\u201d<\/em><br \/>Date: Wednesday, September 28 <br \/>Time: 10:40 AM Eastern Time <br \/>Location: New York, NY<\/p>\n<p align=\"justify\">Dr. Pons and Mr. Peter Garcia, CFO of ALX Oncology, will be hosting one-on-one meetings during the conference. To schedule a one-on-one meeting with the ALX Oncology management team, please contact your Cantor conference representative.<\/p>\n<p align=\"justify\">\n        <strong>About ALX Oncology<\/strong>\n      <\/p>\n<p>ALX Oncology is a publicly traded, clinical-stage immuno-oncology company focused on helping patients fight cancer by developing therapies that block the CD47 checkpoint pathway and bridge the innate and adaptive immune system. ALX Oncology\u2019s lead product candidate, evorpacept, is a next generation CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain. Evorpacept has demonstrated promising clinical responses across a range of hematologic and solid malignancies in combination with a number of leading anti-cancer agents. ALX Oncology intends to continue clinical development of evorpacept for the treatment of multiple solid tumor indications and hematologic malignancies.<\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1MDg4NSM1MTY0NzQ2IzIxOTI4NjM=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/YWJmMmMyMzItM2I1YS00YmI4LWExYjgtZDdhNTBmMGE0MWRjLTEyMDQ0MTY=\/tiny\/ALX-Oncology.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\">\n<pre>Investor Contact:\r\n\r\nPeter Garcia\r\nChief Financial Officer, ALX Oncology\r\n(650) 466-7125 Ext. 113\r\npeter@alxoncology.com\r\n\r\nArgot Partners\r\n(212) 600-1902\r\nalxoncology@argotpartners.com\r\n\r\nMedia Contact:\r\n\r\nKaren Sharma\r\nMacDougall\r\n(781) 235-3060\r\nalx@macbiocom.com<\/pre>\n<\/p><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SOUTH SAN FRANCISCO, Calif., Sept. 21, 2022 (GLOBE NEWSWIRE) &#8212; ALX Oncology Holdings Inc., (\u201cALX Oncology\u201d) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced that Jaume Pons, Ph.D., Founder, President and Chief Executive Officer, will participate in a panel and investor meetings at the Cantor Oncology, Hematology &amp; HemeOnc Conference on Wednesday, September 28 in New York. Format: Moderated panel with analysts, Li Watsek &amp; Brandon FolkesPanel: \u201cBuilding Combinations: What are the Novel Ideas?\u201dDate: Wednesday, September 28 Time: 10:40 AM Eastern Time Location: New York, NY Dr. Pons and Mr. Peter Garcia, CFO of ALX Oncology, will be hosting one-on-one meetings during the conference. To schedule a one-on-one meeting with the ALX &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-to-participate-in-the-cantor-oncology-hematology-hemeonc-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;ALX Oncology to Participate in the Cantor Oncology, Hematology &amp; HemeOnc Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-687720","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>ALX Oncology to Participate in the Cantor Oncology, Hematology &amp; HemeOnc Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-to-participate-in-the-cantor-oncology-hematology-hemeonc-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ALX Oncology to Participate in the Cantor Oncology, Hematology &amp; HemeOnc Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SOUTH SAN FRANCISCO, Calif., Sept. 21, 2022 (GLOBE NEWSWIRE) &#8212; ALX Oncology Holdings Inc., (\u201cALX Oncology\u201d) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced that Jaume Pons, Ph.D., Founder, President and Chief Executive Officer, will participate in a panel and investor meetings at the Cantor Oncology, Hematology &amp; HemeOnc Conference on Wednesday, September 28 in New York. Format: Moderated panel with analysts, Li Watsek &amp; Brandon FolkesPanel: \u201cBuilding Combinations: What are the Novel Ideas?\u201dDate: Wednesday, September 28 Time: 10:40 AM Eastern Time Location: New York, NY Dr. Pons and Mr. Peter Garcia, CFO of ALX Oncology, will be hosting one-on-one meetings during the conference. To schedule a one-on-one meeting with the ALX &hellip; Continue reading &quot;ALX Oncology to Participate in the Cantor Oncology, Hematology &amp; HemeOnc Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-to-participate-in-the-cantor-oncology-hematology-hemeonc-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2022-09-21T20:04:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1MDg4NSM1MTY0NzQ2IzIxOTI4NjM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alx-oncology-to-participate-in-the-cantor-oncology-hematology-hemeonc-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alx-oncology-to-participate-in-the-cantor-oncology-hematology-hemeonc-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"ALX Oncology to Participate in the Cantor Oncology, Hematology &amp; HemeOnc Conference\",\"datePublished\":\"2022-09-21T20:04:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alx-oncology-to-participate-in-the-cantor-oncology-hematology-hemeonc-conference\\\/\"},\"wordCount\":243,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alx-oncology-to-participate-in-the-cantor-oncology-hematology-hemeonc-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1MDg4NSM1MTY0NzQ2IzIxOTI4NjM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alx-oncology-to-participate-in-the-cantor-oncology-hematology-hemeonc-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alx-oncology-to-participate-in-the-cantor-oncology-hematology-hemeonc-conference\\\/\",\"name\":\"ALX Oncology to Participate in the Cantor Oncology, Hematology &amp; HemeOnc Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alx-oncology-to-participate-in-the-cantor-oncology-hematology-hemeonc-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alx-oncology-to-participate-in-the-cantor-oncology-hematology-hemeonc-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1MDg4NSM1MTY0NzQ2IzIxOTI4NjM=\",\"datePublished\":\"2022-09-21T20:04:07+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alx-oncology-to-participate-in-the-cantor-oncology-hematology-hemeonc-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alx-oncology-to-participate-in-the-cantor-oncology-hematology-hemeonc-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alx-oncology-to-participate-in-the-cantor-oncology-hematology-hemeonc-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1MDg4NSM1MTY0NzQ2IzIxOTI4NjM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1MDg4NSM1MTY0NzQ2IzIxOTI4NjM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alx-oncology-to-participate-in-the-cantor-oncology-hematology-hemeonc-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ALX Oncology to Participate in the Cantor Oncology, Hematology &amp; HemeOnc Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ALX Oncology to Participate in the Cantor Oncology, Hematology &amp; HemeOnc Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-to-participate-in-the-cantor-oncology-hematology-hemeonc-conference\/","og_locale":"en_US","og_type":"article","og_title":"ALX Oncology to Participate in the Cantor Oncology, Hematology &amp; HemeOnc Conference - Market Newsdesk","og_description":"SOUTH SAN FRANCISCO, Calif., Sept. 21, 2022 (GLOBE NEWSWIRE) &#8212; ALX Oncology Holdings Inc., (\u201cALX Oncology\u201d) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced that Jaume Pons, Ph.D., Founder, President and Chief Executive Officer, will participate in a panel and investor meetings at the Cantor Oncology, Hematology &amp; HemeOnc Conference on Wednesday, September 28 in New York. Format: Moderated panel with analysts, Li Watsek &amp; Brandon FolkesPanel: \u201cBuilding Combinations: What are the Novel Ideas?\u201dDate: Wednesday, September 28 Time: 10:40 AM Eastern Time Location: New York, NY Dr. Pons and Mr. Peter Garcia, CFO of ALX Oncology, will be hosting one-on-one meetings during the conference. To schedule a one-on-one meeting with the ALX &hellip; Continue reading \"ALX Oncology to Participate in the Cantor Oncology, Hematology &amp; HemeOnc Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-to-participate-in-the-cantor-oncology-hematology-hemeonc-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2022-09-21T20:04:07+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1MDg4NSM1MTY0NzQ2IzIxOTI4NjM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-to-participate-in-the-cantor-oncology-hematology-hemeonc-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-to-participate-in-the-cantor-oncology-hematology-hemeonc-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"ALX Oncology to Participate in the Cantor Oncology, Hematology &amp; HemeOnc Conference","datePublished":"2022-09-21T20:04:07+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-to-participate-in-the-cantor-oncology-hematology-hemeonc-conference\/"},"wordCount":243,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-to-participate-in-the-cantor-oncology-hematology-hemeonc-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1MDg4NSM1MTY0NzQ2IzIxOTI4NjM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-to-participate-in-the-cantor-oncology-hematology-hemeonc-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-to-participate-in-the-cantor-oncology-hematology-hemeonc-conference\/","name":"ALX Oncology to Participate in the Cantor Oncology, Hematology &amp; HemeOnc Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-to-participate-in-the-cantor-oncology-hematology-hemeonc-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-to-participate-in-the-cantor-oncology-hematology-hemeonc-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1MDg4NSM1MTY0NzQ2IzIxOTI4NjM=","datePublished":"2022-09-21T20:04:07+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-to-participate-in-the-cantor-oncology-hematology-hemeonc-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-to-participate-in-the-cantor-oncology-hematology-hemeonc-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-to-participate-in-the-cantor-oncology-hematology-hemeonc-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1MDg4NSM1MTY0NzQ2IzIxOTI4NjM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1MDg4NSM1MTY0NzQ2IzIxOTI4NjM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-to-participate-in-the-cantor-oncology-hematology-hemeonc-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"ALX Oncology to Participate in the Cantor Oncology, Hematology &amp; HemeOnc Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/687720","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=687720"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/687720\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=687720"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=687720"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=687720"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}